Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petros Christopoulos

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
Translational Lung Cancer Research|January 11, 2024
An advanced NSCLC patient with <i>ALK-RNF144A</i> and <i>HIP1-ALK</i> fusions treated with <i>ALK</i>-TKI combination therapy: a case reportHui Li, Jingjing Liu, Shaowei Lan, et al.
Cancers|April 30, 2021
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center AnalysisFlorian Eichhorn, Mark Kriegsmann, Laura V Klotz, et al.
Case Reports in Surgery|December 11, 2012
Retroperitoneal Abscess Formation as a Result of Spilled Gallstones during Laparoscopic Cholecystectomy: An Unusual Case ReportGrigoris Chatzimavroudis, Stefanos Atmatzidis, Basilis Papaziogas, et al.
Oncoimmunology|December 8, 2018
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenJan Budczies, Anja Seidel, Petros Christopoulos, et al.
Cancer & Metabolism|June 16, 2025
Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesisAnn-Kathrin Daum, Lisa Schlicker, Marc A Schneider, et al.
Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.
BMC Cancer|August 27, 2020
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trialFarastuk Bozorgmehr, Inn Chung, Petros Christopoulos, et al.
Translational Lung Cancer Research|June 19, 2025
Impact of omitting clinical target volume in radiotherapy for locally advanced non-small cell lung cancer: a propensity score matching analysisLiang Liu, Wen Bao, Xiaoshuai Yuan, et al.
Cancers|April 30, 2021
Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for RedefinitionPhilip Baum, Samantha Taber, Stella Erdmann, et al.
The American Journal of Surgical Pathology|April 26, 2021
Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the LungAbbas Agaimy, Robert Stoehr, Michael Michal, et al.
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
Translational Lung Cancer Research|January 11, 2024
An advanced NSCLC patient with <i>ALK-RNF144A</i> and <i>HIP1-ALK</i> fusions treated with <i>ALK</i>-TKI combination therapy: a case reportHui Li, Jingjing Liu, Shaowei Lan, et al.
Cancers|April 30, 2021
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center AnalysisFlorian Eichhorn, Mark Kriegsmann, Laura V Klotz, et al.
Case Reports in Surgery|December 11, 2012
Retroperitoneal Abscess Formation as a Result of Spilled Gallstones during Laparoscopic Cholecystectomy: An Unusual Case ReportGrigoris Chatzimavroudis, Stefanos Atmatzidis, Basilis Papaziogas, et al.
Oncoimmunology|December 8, 2018
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenJan Budczies, Anja Seidel, Petros Christopoulos, et al.
Cancer & Metabolism|June 16, 2025
Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesisAnn-Kathrin Daum, Lisa Schlicker, Marc A Schneider, et al.
Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.
BMC Cancer|August 27, 2020
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trialFarastuk Bozorgmehr, Inn Chung, Petros Christopoulos, et al.
Translational Lung Cancer Research|June 19, 2025
Impact of omitting clinical target volume in radiotherapy for locally advanced non-small cell lung cancer: a propensity score matching analysisLiang Liu, Wen Bao, Xiaoshuai Yuan, et al.
Cancers|April 30, 2021
Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for RedefinitionPhilip Baum, Samantha Taber, Stella Erdmann, et al.
The American Journal of Surgical Pathology|April 26, 2021
Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the LungAbbas Agaimy, Robert Stoehr, Michael Michal, et al.
Pageof 18